May 1, 2025 10:09 AM EDTUpdated 10:32 AM
Deals

Af­ter hunt for al­ter­na­tives, Kro­nos Bio se­lects Tang Cap­i­tal's Con­cen­tra for a deal

Kyle LaHucik

Senior Reporter

Kro­nos Bio, the drug de­vel­op­er long led by Gilead vet­er­an Nor­bert Bischof­berg­er, is call­ing it quits.

The biotech said Thurs­day it’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

RFK Jr. claims place­bo-con­trolled vac­cine tri­als are 'rad­i­cal de­par­ture' from past. Ex­perts dis­agree

CROs raise the alarm as clients de­lay R&D plans over fund­ing, tar­iff wor­ries

Arv­inas ends plans for two Phase 3 breast can­cer tri­als; Phath­om makes cuts

Lil­ly meets sales ex­pec­ta­tions, but No­vo gains on PBM win

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times